PortalPublikationenProstate-specific Membrane Antigen Radioguidance for Salvage...

Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer

Standard

Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer. / Knipper, Sophie; Budäus, Lars; Graefen, Markus; Maurer, Tobias.

in: EUR UROL FOCUS, Jahrgang 7, Nr. 2, 03.2021, S. 294-296.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › Andere (Vorworte u.ä.) › Forschung

Harvard

Knipper, S, Budäus, L, Graefen, M & Maurer, T 2021, 'Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer', EUR UROL FOCUS, Jg. 7, Nr. 2, S. 294-296. https://doi.org/10.1016/j.euf.2021.01.015

APA

Knipper, S., Budäus, L., Graefen, M., & Maurer, T. (2021). Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer. EUR UROL FOCUS, 7(2), 294-296. https://doi.org/10.1016/j.euf.2021.01.015

Vancouver

Knipper S, Budäus L, Graefen M, Maurer T. Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer. EUR UROL FOCUS. 2021 Mär;7(2):294-296. https://doi.org/10.1016/j.euf.2021.01.015

Bibtex

@article{076561ee8154449fba73e17c2687158d,
title = "Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer",
abstract = "Prostate-specific membrane antigen (PSMA)-based radioguidance for salvage lymph node dissection (sLND) in recurrent prostate cancer has shown promising early oncological outcomes. However, long-term outcomes are still undetermined. Future studies are needed before introducing PSMA positron emission tomography-based sLND into routine clinical practice outside of clinical trials or registries.",
author = "Sophie Knipper and Lars Bud{\"a}us and Markus Graefen and Tobias Maurer",
note = "Copyright {\textcopyright} 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.",
year = "2021",
month = mar,
doi = "10.1016/j.euf.2021.01.015",
language = "English",
volume = "7",
pages = "294--296",
journal = "EUR UROL FOCUS",
issn = "2405-4569",
publisher = "Elsevier BV",
number = "2",

}

RIS

TY - JOUR

T1 - Prostate-specific Membrane Antigen Radioguidance for Salvage Lymph Node Dissection in Recurrent Prostate Cancer

AU - Knipper, Sophie

AU - Budäus, Lars

AU - Graefen, Markus

AU - Maurer, Tobias

N1 - Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

PY - 2021/3

Y1 - 2021/3

N2 - Prostate-specific membrane antigen (PSMA)-based radioguidance for salvage lymph node dissection (sLND) in recurrent prostate cancer has shown promising early oncological outcomes. However, long-term outcomes are still undetermined. Future studies are needed before introducing PSMA positron emission tomography-based sLND into routine clinical practice outside of clinical trials or registries.

AB - Prostate-specific membrane antigen (PSMA)-based radioguidance for salvage lymph node dissection (sLND) in recurrent prostate cancer has shown promising early oncological outcomes. However, long-term outcomes are still undetermined. Future studies are needed before introducing PSMA positron emission tomography-based sLND into routine clinical practice outside of clinical trials or registries.

U2 - 10.1016/j.euf.2021.01.015

DO - 10.1016/j.euf.2021.01.015

M3 - Other (editorial matter etc.)

C2 - 33558200

VL - 7

SP - 294

EP - 296

JO - EUR UROL FOCUS

JF - EUR UROL FOCUS

SN - 2405-4569

IS - 2

ER -